Xenetic Biosciences, Inc. has opened its new corporate headquarters and R&D facility in Lexington, MA. The company has relocated from London, UK and currently has seven employees in Lexington with plans to grow to 14 by the end of the year.
Scott Maguire, chief executive officer of Xenetic said, "The opening of Xenetic's new corporate headquarters in Lexington marks an important new phase in the company's 17-year history. Moving our development operations to the MA biotech corridor is an important step in our transition to becoming an innovative biopharmaceutical company based and publicly listed in the U.S. We believe that we are much more strongly positioned to execute on our mission to develop and commercialize leading next-generation biologic drugs and novel oncology therapeutics."
Robert Coughlin, president and chief executive officer of MassBio said, "We are very excited by Xenetic's decision to relocate to Massachusetts. We look forward to working with Xenetic in the years ahead as the Company continues its growth as a U.S.-listed company."